Pressmeddelanden

Lipigon Pharmaceuticals announces collaboration with Singapore lung health initiative TARIPH and Shenzhen Institutes of Advanced Technology to study a potential novel treatment for COVID-19

Lipigon Pharmaceuticals AB ("Lipigon"), today announced that the company has entered into a collaboration agreement with The Academic Respiratory Initiative for Pulmonary Health (TARIPH) at Nanyang Technological University, Singapore ("NTU Singapore") and Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (SIAT). The parties will collaborate on a potential novel treatment for Acute Respiratory Distress Syndrome (ARDS), a common and lethal co-morbidity of pneumonia caused by SARS-CoV-2 pandemic and other infectious lung disorders.

"This is a strategically important collaboration that allows Lipigon to test its drug candidates for potential use in treatment in Covid-19 and other infectious lung diseases. It is a great opportunity for us to work with leading experts in this area" explains CEO and co-founder Dr. Stefan K Nilsson.

Lipigon,TARIPH and SIAT will collaborate in the validation of antisense oligonucleotide (ASO) drug candidates targeting angiopoietin-like 4 (ANGPTL4). As part of TARIPH, Associate Professor Nguan Soon Tan's research group at NTU's Lee Kong Chian School of Medicine has shown in several publications that ANGPTL4 plays an important role in lung injury, as it was among the most significantly upregulated genes in the 1918 Spanish flu and 2009 H1N1 swine flu pandemics.

Lipigon has developed ASO drug candidates targeting ANGPTL4 that potentially could treat patients suffering from inflammation-associated lung injury including ARDS. These compounds will be tested by Professor Tan and collaborators, in advanced disease models to provide proof-of-concept for this novel treatment. The compounds have been optimized for efficacy and safety by Lipigon. If proven efficient for treating ARDS these compounds could immediately enter non-clinical safety trials.

"Professor Tan's outstanding research on pulmonary vasculature leakiness and pathological angiogenesis has established ANGPTL4 as a promising drug target. We are extremely happy and fortunate to enter this collaboration which gives our compounds a fast-track to proof of concept in relevant disease models", said Dr. Stefan K. Nilsson. "The SAR-CoV-2 pandemic has pinpointed a significant medical need for novel treatments of all infectious lung diseases. We believe that ANGPTL4 inhibition could make a difference for millions of patients every year".

"Over the last decade, our laboratory findings have suggested that when the expression of ANGPTL4 is suppressed, the duration and severity of lung damage is also reduced, suggesting a strong possibility for faster recovery. I hope our collaboration will lead to significant clinical benefit to patients suffering from lung injury caused by severe pneumonia," said Associate Professor Nguan Soon Tan.

"Our research on ANGPTL4 function in acute lung injury showed potential of ANGPTL4 as a broadspectrum therapy target for pneumonia. We hope our collaboration can provide new tools for clinicians," said Associate Professor Liang Li.

To accelerate the preclinical validation of ANGPTL4 ASO for lung injury, research will be carried out by Professor Tan and his colleagues, including Provost's Chair in Molecular Medicine Assistant Professor Sanjay Chotirmall and Dr Louisa Chan from LKCMedicine, as well as Associate Professor Li Liang from Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.

 

Press Release September 22nd, 2020

For further information, please contact:

Stefan K Nilsson, CEO Lipigon

Mobile +46 70-578 17 68

Mail: stefan@lipigon.se

www.lipigon.se

About ANGPTL4 and ARDS

Pneumonia kill millions of individuals, most commonly from severe inflammatory response causing damages to the lungs. ANGPTL4 is a gene associated with acute lung injury in both viral and bacterial pneumonia; mainly by promoting pathological angiogenesis and vascular leakage. Infectious lung disease may lead to acute respiratory distress syndrome (ARDS) which is a life-threatening syndrome characterized by acute inflammation in combination with respiratory failure. Patients are commonly treated with oxygen and often mechanical ventilation at intensive care units. Treatment of the infection that causes pneumonia is sometimes not possible, as in the case of SARS-CoV-2 infection and COVID-19, thus there is a great unmet medical need for novel ARDS treatments.

About Lipigon Pharmaceuticals AB

Lipigon develops novel therapeutics for patients with lipid-related disorders. The company is a spin-off from Umeå University, Sweden, based on five decades of lipid research. Our primary focus is orphan lipid disorders and in addition to the ANGPTL antisense program, Lipigon's pipeline includes a program for gene therapy in lipodystrophy, together with Combigene AB (publ) and a small molecule program in collaboration with HitGen (Inc). 

2021-11-24
Regulatorisk

Lipigon Pharmaceuticals AB ("Lipigon") publicerar i dag sin delårsrapport för perioden 1 januari-30 september 2021. Delårsrapporten i sin helhet finns tillgänglig som bifogad fil samt på bolagets hemsida, lipigon.se. Nedan följer en sammanfattning.

2021-11-04

Lipigon Pharmaceuticals AB ("Lipigon"), som utvecklar läkemedel mot sjukdomar orsakade av störningar i kroppens förmåga att hantera fetter, tillkännager i dag att bolaget ingått partnerskap med 5Prime Sciences ("5Prime"). Samarbetet syftar till att accelerera utvecklingsarbetet inför de kliniska prövningarna med huvudkandidaten Lipisense. Genom att använda avancerade genetiska verktyg och storskaliga samlingar av patientkohorter med miljarder datapunkter kommer 5Prime bland annat att undersöka vilka patientgrupper som kommer att dra mest nytta av en hämning av målproteinet ANGPTL4. Partnerskapet innebär att 5Prime blir Lipigons inhouse-team för humangenetik.

2021-11-04

This is an English translation of the Swedish original. In case of discrepancies, the Swedish original shall prevail.

Lipigon Pharmaceuticals AB ("Lipigon"), developer of therapeutics for lipid-related diseases, today announced a partnership with 5Prime Sciences ("5Prime") to accelerate the development of the lipid-lowering drug candidate Lipisense for upcoming clinical trials. By utilizing advanced genetic tools and large-scale collections of patient cohorts, providing billions of data points, 5Prime will, among other things, investigate which patient groups will benefit the most from ANGPTL4 inhibition. By partnering, 5Prime will become Lipigon's in-house human genetics team.

2021-10-11

I en intervju i samband med Lipigons presentation på Umeå på börsen berättar vd Stefan K. Nilsson om de senaste studieresultaten i huvudprojektet Lipisense, betydelsen av tidiga effektmått och de speciella egenskaperna med RNA-läkemedel.

2021-09-29

Umeåbaserade Lipigon Pharmaceuticals AB ("Lipigon") deltar i dag på eventet Umeå på börsen. Vd Stefan K. Nilsson berättar om utvecklingen av nya läkemedel mot sjukdomar orsakade av rubbningar i kroppens hantering av fetter, så kallade lipidrelaterade sjukdomar.

2021-09-27

Umeåbaserade Lipigon Pharmaceuticals AB ("Lipigon") kommer att delta på eventet Umeå på börsen onsdagen den 29 september. Vd Stefan K. Nilsson berättar om utvecklingen av nya läkemedel mot sjukdomar orsakade av rubbningar i kroppens hantering av fetter, så kallade lipidrelaterade sjukdomar.

2021-09-23

Lipigon Pharmaceuticals AB ("Lipigon"), som utvecklar nya behandlingar mot sjukdomar orsakade av rubbningar i kroppens hantering av fetter, så kallade lipidrelaterade sjukdomar, presenterade i går läkemedelskandidaten Lipisense vid industrikonferensen TIDES USA i Boston. Konferensen är känd som den främsta inom läkemedelsfälten oligonukleotider, peptider, mRNA och geneditering.

2021-09-14

Lipigon följer tidsplanen inför kommande kliniska studier med den första säkerhetsstudien nu avklarad. Analysguiden är positiva i en uppdaterad analys av bolaget och ser ett motiverat värde om 16-17 kronor per aktie.

2021-09-13

Umeåbaserade Lipigon Pharmaceuticals AB ("Lipigon") kommer att delta på eventet Umeå på börsen onsdagen den 29 september. Vd Stefan K. Nilsson berättar om utvecklingen av nya läkemedel mot sjukdomar orsakade av rubbningar i kroppens hantering av fetter, så kallade lipidrelaterade sjukdomar.

2021-09-10
Regulatorisk

Lipigon Pharmaceuticals AB ("Lipigon"), som utvecklar nya behandlingar mot förhöjda blodfetter, så kallade lipidrelaterade sjukdomar, rapporterar i dag att man slutfört den första av tre prekliniska säkerhetsstudier för läkemedelskandidaten Lipisense. Studien som i första hand är förberedande inför kommande, längre studier visade att Lipisense kan ges i höga doser utan att oönskade biverkningar observerades. Utöver detta visade studien att Lipisense effektivt sänkte nivåerna av blodfettet triglycerid.

2021-09-10
Regulatorisk

This is an English translation of the Swedish original. In case of discrepancies, the Swedish original shall prevail.

Lipigon Pharmaceuticals AB ("Lipigon"), a biotech company developing therapeutics for lipid-related diseases, today announced the completion of the first of three preclinical safety studies for the drug candidate Lipisense. The study, which is primarily preparatory for future, longer studies, showed that Lipisense can be given in high doses with no undesirable side effects observed. In addition, the study showed that Lipisense effectively lowered blood triglyceride levels.

1
2
...
7
>>

Nyheter

24 november, 2021, Pressmeddelande

Lipigon publicerar delårsrapport januari-september 2021

Lipigon Pharmaceuticals AB ("Lipigon") publicerar i dag sin delårsrapport för perioden 1 januari-30 ...

4 november, 2021, Pressmeddelande

Lipigon och 5Prime Sciences ingår partnerskap för att optimera kommande kliniska prövningar

Lipigon Pharmaceuticals AB ("Lipigon"), som utvecklar läkemedel mot sjukdomar orsakade av störningar...

4 november, 2021, Pressmeddelande

Lipigon and 5Prime Sciences enter partnership to optimize coming clinical trials

This is an English translation of the Swedish original. In case of discrepancies, the Swedish origin...

11 oktober, 2021, Pressmeddelande

Effektmått redan i tidig fas - Lipigons vd intervjuas om flaggskeppet Lipisense

I en intervju i samband med Lipigons presentation på Umeå på börsen berättar vd Stefan K. Nilsson om...